Envision Healthcare (EVHC) Price Target Raised to $43.50
Envision Healthcare (NYSE:EVHC) had its target price upped by equities researchers at Credit Suisse Group from $36.00 to $43.50 in a report released on Wednesday. The brokerage presently has a “positive” rating on the stock. Credit Suisse Group’s price objective would indicate a potential upside of 21.85% from the stock’s current price.
Several other research analysts also recently issued reports on EVHC. Mizuho set a $35.00 price objective on shares of Envision Healthcare and gave the stock a “hold” rating in a research report on Wednesday, January 24th. KeyCorp lowered their price objective on shares of Envision Healthcare from $67.00 to $37.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd. Robert W. Baird reaffirmed a “buy” rating and issued a $70.00 target price on shares of Envision Healthcare in a report on Tuesday, October 17th. SunTrust Banks set a $40.00 target price on shares of Envision Healthcare and gave the company a “buy” rating in a report on Thursday, December 21st. Finally, Stephens reaffirmed a “hold” rating and issued a $34.00 target price on shares of Envision Healthcare in a report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $41.50.
Envision Healthcare (NYSE:EVHC) opened at $35.70 on Wednesday. Envision Healthcare has a 52-week low of $23.77 and a 52-week high of $73.00. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.01. The stock has a market cap of $4,350.81 and a price-to-earnings ratio of -7.14.
Large investors have recently modified their holdings of the company. Boston Partners boosted its holdings in Envision Healthcare by 185.6% during the fourth quarter. Boston Partners now owns 220,918 shares of the company’s stock worth $7,635,000 after buying an additional 143,573 shares in the last quarter. CIBC World Markets Inc. purchased a new stake in Envision Healthcare during the fourth quarter worth about $208,000. Quantitative Systematic Strategies LLC boosted its holdings in Envision Healthcare by 17.9% during the fourth quarter. Quantitative Systematic Strategies LLC now owns 14,319 shares of the company’s stock worth $495,000 after buying an additional 2,169 shares in the last quarter. Parametrica Management Ltd purchased a new stake in Envision Healthcare during the fourth quarter worth about $236,000. Finally, Mutual of America Capital Management LLC boosted its holdings in Envision Healthcare by 86.4% during the fourth quarter. Mutual of America Capital Management LLC now owns 162,183 shares of the company’s stock worth $5,605,000 after buying an additional 75,158 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/31/envision-healthcare-evhc-given-new-43-50-price-target-at-credit-suisse-group.html.
Envision Healthcare Company Profile
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.
Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.